Navigation Links
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
Date:6/11/2008

Quark will lead a lecture and present a poster on proprietary siRNA

targeting and delivery approaches

FREMONT, Calif., June 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced it will participate in the Cambridge Healthcare Institute's 9th Annual Beyond Genome Conference on June 8-11, 2008 at The Fairmont Hotel, San Francisco, CA.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals will be presenting a lecture, "Temporary Inhibition of p53 of siRNA for Prevention of Acute Renal Failure: From Concept to Clinical Trials," at 1:50 PM (PT) on June 11, 2008.

Dr. Feinstein's lecture will discuss AKIi-5 and Quark's proprietary concept of temporarily inhibiting p53 as a systemic therapy to prevent the development of acute kidney injury (AKI) in response to ischemia-reperfusion stress. Following a successful preclinical program focused on safety, AKIi-5 is currently in Phase I clinical trials and represents the first ever systemic dosing of an siRNA in humans.

Dr. Swetlana Boldin-Adamsky, Project Director of Quark, will give a poster presentation, "Non-invasive Aerosol siRNA Delivery for the Treatment of Lung Tumors." The poster will discuss direct delivery of siRNA to the respiratory system by inhalation, a potential delivery method for various disorders, including lung cancer. Remarkably, the anti-cancer siRNA target utilized in these studies was discovered using Quark's proprietary BiFAR functional gene discovery platform. Targeting this gene for cancer treatment is covered by Quark's intellectual property.

Dr. Feinstein stated, "We are excited to participate in this year's Beyond Genome conference. We have successfully administered the first siRNA drug candidate systemically in humans with the initiation of our AKIi-5 Phase I clinical trial. This acc
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
5. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
6. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
7. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
8. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
(Date:5/5/2015)... Mich. (PRWEB) May 05, 2015 ... publishing services to develop custom course materials for smaller ... annual enrollments as low as 200 students. , ... a broader range of higher education instructors,” said Jeff ... the country, we can do our part to make ...
(Date:5/5/2015)... May 5, 2015  Renova™ Therapeutics, a biopharmaceutical ... failure and other chronic diseases, has engaged RAND ... designed to reflect the healthcare patterns of multiple ... will be used to characterize the impact the ... on those groups of patients and the overall ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Franz Inc ... technology, today announced that its flagship product, AllegroGraph, has been ... Graph Database Market Update report. AllegroGraph is a ... the W3C industry standards. Graph databases are skyrocketing in popularity ... according to a recent DBMS ranking by DB-Engines. ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... , , SOUTH SAN FRANCISCO, ... ) today announced the sale of 3,489,728 of its ... of approximately $6.5 million, or approximately $1.87 per share, ... The Company intends to use the proceeds from this ...
... LEIDEN, The Netherlands, December 22 Dosage,recommendations for newborns being ... most likely be based on more individual characteristics than,just body ... the Dutch Top,Institute Pharma in which Leiden University (Prof M. ... Tibboel),are represented. , Catherijne Knibbe, clinical ...
... Dec. 21 Ipsogen SA (Alternext: ALIPS) today announced ... tumor grade in chemotherapy prescription has been presented at ... December 9-13, 2009. , The study was conducted ... Using the centre database and a classification tree method, ...
Cached Biology Technology:Poniard Pharmaceuticals Announces $6.5 Million Financing 2Poniard Pharmaceuticals Announces $6.5 Million Financing 3Research: Dosage of Morphine for ill Newborns Still too Imprecise 2Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium 2
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... of the marine food chain, albatrosses accumulate toxic contaminants ... A new study has found dramatic differences in contaminant ... in different areas of the North Pacific. Researchers also ... in both species over the past ten years. , ...
... scrubbing off and discarding the outer layer of long-grain ... the first time, scientists in Japan have shown that ... significantly lowers blood pressure in rats whose hypertension resembles ... in the March 8 issue of the Journal ...
... a blueprint for boosting anti-cancer drugs' effectiveness and lowering ... sinker onto the drugs. This extra weight makes the ... Chemotherapy drugs often fall short of achieving their full ... the tumor too rapidly, said the scientists from Duke ...
Cached Biology News:Albatross study shows regional differences in ocean contamination 2Albatross study shows regional differences in ocean contamination 3How nice, brown rice: Study shows rice bran lowers blood pressure in rats 2Weighting cancer drugs to make them hit tumors harder 2Weighting cancer drugs to make them hit tumors harder 3Weighting cancer drugs to make them hit tumors harder 4
Request Info...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
TCP-1 alpha (H-110)...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: